Late-Stage Melanoma Hits Black Patients at 3x the Rate of White Patients
Black patients face three times the late-stage melanoma diagnosis rate of white patients. Downie outlines the counseling shifts, bemotrizinol's June 2026 FDA approval, and AI's limits.
